Analysts Set VolitionRX Limited (NYSEAMERICAN:VNRX) Target Price at $46.67

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $46.6667.

Several research firms have issued reports on VNRX. Citigroup lowered shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. Benchmark restated a “hold” rating on shares of VolitionRX in a research report on Tuesday. HC Wainwright cut their price target on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th.

VolitionRX Stock Down 10.5%

NYSEAMERICAN VNRX opened at $1.79 on Tuesday. The company has a 50-day simple moving average of $2.90 and a two-hundred day simple moving average of $4.37. VolitionRX has a 12-month low of $1.75 and a 12-month high of $18.80. The firm has a market cap of $15.45 million, a price-to-earnings ratio of -0.43 and a beta of 1.04.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The business had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.52 million. Equities analysts expect that VolitionRX will post -2.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRX

Several hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC raised its stake in shares of VolitionRX by 166.6% during the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67,848 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of VolitionRX during the fourth quarter valued at about $34,000. Jane Street Group LLC bought a new position in shares of VolitionRX during the fourth quarter valued at about $28,000. Geode Capital Management LLC raised its stake in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares during the last quarter. Finally, Armistice Capital LLC raised its stake in shares of VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares during the last quarter. 8.09% of the stock is owned by institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.